vTv Therapeutics Inc.

Equities

VTVT

US9183852048

Biotechnology & Medical Research

Delayed Nasdaq 09:30:00 2024-03-28 am EDT 5-day change 1st Jan Change
24.36 USD +2.35% Intraday chart for vTv Therapeutics Inc. -10.76% +106.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
VTv Therapeutics Inc. Announces Board Changes CI
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
VTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes CI
Top Midday Gainers MT
VTv Therapeutics Inc. Announces Board Changes CI
VTv Therapeutics Inc. announced that it has received $50.961457 million in funding from JDRF T1D Fund, Samsara BioCapital LLC and another investors CI
Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer CI
North American Morning Briefing : China Trouble -2- DJ
VTv Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
VTv Therapeutics Says Cantex Pharmaceuticals Received IP License for Azeliragon MT
Cantex Pharmaceuticals Receives US Patent Covering vTv Therapeutics' Azeliragon MT
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Earnings Flash (VTVT) VTV THERAPEUTICS Reports Q4 Revenue $9,000 MT
VTv Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
VTv Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
VTv Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
VTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel CI
VTv Therapeutics Names Steven Tuch Finance Chief MT
VTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer CI
VTv Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Northland Securities Raises Price Target on vTv Therapeutics to $2 From $1.50, Maintains Outperform Rating MT
VTv Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart vTv Therapeutics Inc.
More charts
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock vTv Therapeutics Inc. - Nasdaq
  4. News vTv Therapeutics Inc.
  5. vTv Therapeutics : Health Care Stocks Retreat Friday